North American adult T-cell leukemia/lymphoma (NA-ATLL) has poor outcomes and limited therapeutic options. In a small case series, peginterferon-alfa-2a plus bictegravir/emtricitabine/tenofovir alafenamide, with selective venetoclax, suppressed HTLV-1, reduced circulating ATLL burden, supporting the prospective evaluation of this treatment modality.
No takes yet. Share an insight, caveat, or question.
Tanwar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: